TRACON Pharmaceuticals Appoints Brenda Marczi as Senior Vice President, Regulatory Affairs
July 20, 2021 at 08:05 am EDT
Share
TRACON Pharmaceuticals announced the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs. Dr. Marczi brings more than three decades of regulatory affairs experience to TRACON. Dr. Marczi’s past roles include Vice President, Regulatory Affairs at Ferring Pharmaceuticals where she was responsible for all U.S. regulatory activities, including the launch and commercialization activities for the breakthrough designation gene therapy product for non-muscle invasive bladder cancer.
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
TRACON PHARMACEUTICALS, INC. 
